.jpg)
14 hours ago
2
Article content
Appili Presentation Highlights Recent Collaborations and Funding Milestones
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities
Article content
Article content
HALIFAX, Nova Scotia, March 30, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that President and Chief Executive Officer Dr. Don Cilla and Chief Development Officer, Dr. Gary Nabors will exhibit at the World Vaccine Congress Washington 2026.
Article content
Article content
“The World Vaccine Congress Washington provides an important venue to engage with global vaccine experts and government leaders,” said Dr. Cilla, President and CEO of Appili Therapeutics. “At the congress, Appili will be focused on accelerating discussions with government and industry leaders to expand our non-dilutive funding base.”
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
At the World Vaccine Congress, Dr. Cilla and Dr. Nabors will meet with global vaccine leaders, potential collaborators, and funding partners to showcase Appili’s collaborative infectious disease portfolio. Discussions will spotlight:
Article content
- US $40 million funding award from National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to support collaborated development of fungal vaccine
- ATI-1701, an in-licensed tularemia vaccine advancing under a US $11.7 million U.S. Air Force Academy award
- LIKMEZ, a partnered liquid metronidazole product launched in the U.S.
- ATI-1801, an in-licensed topical paromomycin product to treat leishmaniasis, with demonstrated Phase 3 efficacy
Article content
The Company will also exhibit in the Emerging Business Zone (Booth #585).
Article content
Article content
Exhibit details:
Article content
Title: Advancing Strategic Collaborations for Infectious Disease Products
Booth: #585, Emerging Business Zone
Dates: March 31 – April 2, 2026
Article content
For meeting requests at the World Vaccine Congress, please contact [email protected].
Article content
About the World Vaccine Congress Washington
Article content
The World Vaccine Congress is a series of conferences and exhibitions that have grown over 25 years to become the largest vaccine meetings of their kind across the globe. The event format allows for whole-sector topics with hundreds of speakers and covers the complete vaccine value chain, enabling thousands of attendees from science, government, and manufacturers to come together to create ground-breaking progress. More information can be found at https://www.terrapinn.com/conference/world-vaccine-congress-washington/index.stm
Article content
About Appili Therapeutics
Article content
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
Article content
Contacts:
Article content
Media:
Jenna McNeil, Communications Manager
Appili Therapeutics
E: [email protected]
Article content
Investor Relations:
Don Cilla, Pharm.D., M.B.A., President and CEO
Appili Therapeutics
E: [email protected]
Article content
Article content
Article content
Article content
Article content
Article content
English (US)